Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO dual PPARα/δ activation impacts inflammation and fibrosisPPARα activation linked to fatigue improvement in primary biliary cholangitis PARIS, FRANCE, 7 May 2025 Today, Ipsen (Eur...
De nouvelles données issues d’analyses exploratoires soulignent l’impact d’IQIRVO® (élafibranor) sur la fatigue et mettent en lumière son mécanisme d’action sur l’inflammation et les symptômes associés à la cholangite biliaire primitive D’autres données nouvelles suggèrent que jusqu’à deux fois plus de patients traités avec IQIRVO® ont constaté une amélioration cliniquement significative de la fatigue par rapport au placebo après 52 semaines de traitement.La double activation PPARα/δ produit un effet sur l’inflammation et la fibrose.L’activation de PPARα a été associée à une amélioration de...
ArcelorMittal announces results of its General Meeting 6 May 2025, 15.15 CET The Annual General Meeting (‘General Meeting’) of shareholders of ArcelorMittal (the “Company”) held today in Luxembourg approved all resolutions by a strong majority. 71.73% of the voting rights were represented at the General Meeting. The results of the votes will be posted shortly on under “Investors – Equity investors – Shareholders events – AGM – Annual General Meeting of shareholders, 6 May 2025” where the full documentation regarding the General Meeting is available. In particular, the shareholders: App...
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura’s involvement in major transformation projects across leadin...
Ipsen nomme Laura Réveillon au poste de Vice-Présidente Exécutive, Stratégie et Transformation PARIS, FRANCE, 6 mai 2025 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui la nomination de Laura Réveillon, PhD, au poste de Vice-Présidente Exécutive, Stratégie et Transformation, à compter du 14 mai 2025. Elle fera partie de l'équipe de direction (ELT) et reportera directement au Directeur Général (CEO) d'Ipsen, David Loew. « Nous sommes très heureux d'accueillir Laura chez Ipsen en tant que Vice-Présidente Exécutive, Stratégie e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.